Literature DB >> 12062123

Glutathione induces cellular resistance against cationic dinuclear platinum anticancer drugs.

Bart A J Jansen1, Jaap Brouwer, Jan Reedijk.   

Abstract

The sulfur-containing tripeptide glutathione (GSH) is one of the most abundant molecules in cells. Elevated levels of GSH render some types of cancer cells resistant against well-known platinum anti-cancer drugs such as cisplatin and carboplatin. Platinum complexes are often very reactive towards the cysteine residue of GSH, which detoxifies these compounds by a rapid binding mechanism. Clearly, this resistance mechanism poses a severe obstacle to any new platinum drugs designed to overcome cisplatin resistance. In the present study the cytotoxicity of dinuclear platinum compounds of the 1,1/t,t type, as developed by Farrell, is determined in human ovarium A2780 cells and in the cisplatin-resistant cell line A2780cisR, which possesses elevated levels of GSH. Further, the effect of depletion of GSH levels by L-buthionine-S,R-sulfoximine (L-BSO) in A2780cisR was investigated. The experiments show that detoxification by GSH is an effective resistance mechanism against dinuclear platinum compounds. However, the dinuclear complexes are less sensitive towards detoxification compared to cisplatin. This is probably because of the rapid binding of dinuclear cationic complexes to DNA. Compared to cisplatin, the rapid binding to DNA reduces the time during which the drug molecules are exposed to GSH in the cytosol. The reaction of a representative dinuclear compound with glutathione (pH 7, 37 degrees C) was studied in detail by 195Pt NMR. The dinuclear complex BBR3005 ([trans-PtCl(2)(NH(3))(2)(mu-H(2)N(CH(2))(6)NH(2))](2+), abbreviated as 1,1/t,t n=6), follows different pathways in the reaction with GSH, depending on the molar ratio of the reactants. When reacted in stoichiometric amounts (1:1), first a chloride on each platinum is replaced by a sulfur, forming a PtN(3)S product at -2977 ppm. After 2-3 h, this intermediate reacts further to form a sulfur-bridged N(3)Pt-S-PtN(3) species as the main product at -2811 ppm. When BBR3005 is reacted with GSH in a ratio of 1:4, the sulfur-bridged species is not observed. Instead, the final product is trans-Pt(GS)(2)(NH(3))(2) (at -3215 ppm); the same product appears if GSH is reacted with trans-PtCl(2)(NH(3))(2). Apparently, GSH first replaces the chlorides and subsequently degrades the dinuclear compound by replacement of the diaminealkyl linker.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12062123     DOI: 10.1016/s0162-0134(02)00381-1

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  25 in total

1.  The trans influence in the modulation of platinum anticancer agent biology: the effect of nitrite leaving group on aquation, reactions with S-nucleophiles and DNA binding of dinuclear and trinuclear compounds.

Authors:  Eva I Montero; Junyong Zhang; Joseph J Moniodis; Susan J Berners-Price; Nicholas P Farrell
Journal:  Chemistry       Date:  2010-08-09       Impact factor: 5.236

2.  Exogenous glutathione contributes to cisplatin resistance in lung cancer A549 cells.

Authors:  Dong Lan; Li Wang; Rongquan He; Jie Ma; Yehong Bin; Xiaojv Chi; Gang Chen; Zhengwen Cai
Journal:  Am J Transl Res       Date:  2018-05-15       Impact factor: 4.060

Review 3.  Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.

Authors:  Spyridon P Basourakos; Likun Li; Ana M Aparicio; Paul G Corn; Jeri Kim; Timothy C Thompson
Journal:  Curr Med Chem       Date:  2017       Impact factor: 4.530

4.  Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK.

Authors:  Nathan M Weir; Karuppaiyah Selvendiran; Vijay Kumar Kutala; Liyue Tong; Shilpa Vishwanath; Murugesan Rajaram; Susheela Tridandapani; Shrikant Anant; Periannan Kuppusamy
Journal:  Cancer Biol Ther       Date:  2007-02-05       Impact factor: 4.742

5.  Mechanisms underlying reductant-induced reactive oxygen species formation by anticancer copper(II) compounds.

Authors:  Christian R Kowol; Petra Heffeter; Walter Miklos; Lars Gille; Robert Trondl; Loredana Cappellacci; Walter Berger; Bernhard K Keppler
Journal:  J Biol Inorg Chem       Date:  2011-12-22       Impact factor: 3.358

6.  Cell-cycle inhibition and apoptosis induced by curcumin and cisplatin or oxaliplatin in human ovarian carcinoma cells.

Authors:  M Montopoli; E Ragazzi; G Froldi; L Caparrotta
Journal:  Cell Prolif       Date:  2009-02-18       Impact factor: 6.831

7.  DOXIL when combined with Withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancer.

Authors:  Sham S Kakar; Christopher A Worth; Zhenglong Wang; Kelsey Carter; Mariusz Ratajczak; Pranesh Gunjal
Journal:  J Cancer Stem Cell Res       Date:  2016-04-19

8.  Dinuclear platinum complexes with N, N'-bis(aminoalkyl)-1,4-diaminoanthraquinones as linking ligands. Part II. Cellular processing in A2780 cisplatin-resistant human ovarian carcinoma cells: new insights into the mechanism of resistance.

Authors:  Ganna V Kalayda; Bart A J Jansen; Chris Molenaar; Peter Wielaard; Hans J Tanke; Jan Reedijk
Journal:  J Biol Inorg Chem       Date:  2004-04-08       Impact factor: 3.358

9.  Dinuclear platinum complexes with N, N'-bis(aminoalkyl)-1,4-diaminoanthraquinones as linking ligands. Part I. Synthesis, cytotoxicity, and cellular studies in A2780 human ovarian carcinoma cells.

Authors:  Bart A J Jansen; Peter Wielaard; Ganna V Kalayda; Maura Ferrari; Chris Molenaar; Hans J Tanke; Jaap Brouwer; Jan Reedijk
Journal:  J Biol Inorg Chem       Date:  2004-04-08       Impact factor: 3.358

10.  Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy.

Authors:  Helen H W Chen; Macus Tien Kuo
Journal:  Met Based Drugs       Date:  2010-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.